Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.
SC forimtamig demonstrated potent and durable activity in RRMM, which could be enhanced with a condensed step-up schedule, highlighting the narrow therapeutic window for GPRC5D as a target for T-cell-engaging bispecific antibodies.